NMRA Overview

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Wall Street analysts forecast NMRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NMRA is9.33 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neumora Therapeutics Inc revenue for the last quarter amounts to -52.70M USD, decreased -31.24

Neumora Therapeutics Inc. EPS for the last quarter amounts to -46649000.00 USD, increased 39.32

Neumora Therapeutics Inc (NMRA) has 110 emplpoyees as of March 23 2026.

Today NMRA has the market capitalization of 426.55M USD.